Advertisement

Tumor Biology

, Volume 35, Issue 6, pp 5787–5795 | Cite as

Esophageal cancer-selective expression of TRAIL mediated by MREs of miR-143 and miR-122

  • Kun Zhou
  • Yan Yan
  • Song Zhao
Research Article

Abstract

Esophageal cancer is one of the most common digestive system neoplasms and has a quite poor prognosis. TNF-related apoptosis-inducing ligand (TRAIL) induces the apoptosis in a wide range of cancer cells including esophageal cancers. However, TRAIL also activates apoptotic pathway in normal cells. To improve the specificity of TRAIL action, we employed the microRNA (miRNA) response elements (MREs) of miR-143 and miR-122 to restrict TRAIL expression mediated by an adenoviral vector (Ad-TRAIL-143-122) in esophageal cancer cells. The experiments showed that Ad-TRAIL-143-122 was able to highly express TRAIL in esophageal cancer cells, but not normal cells. The selective TRAIL expression also led to selective apoptosis in esophageal cancer cells. Ad-TRAIL-143-122 greatly reduced the viability of esophageal cancer cells without cytotoxicity to normal cells. In mice, Ad-TRAIL-143-122 suppressed the growth of esophageal cancer xenografts and protected liver from TRAIL-induced toxicity. In this study, we constructed a biologic vector that can express exogenous genes in a tumor-specific manner. This strategy can simultaneously treat cancer and prevent hepatoxicity and thus may be a promising way for esophageal cancer treatment.

Keywords

Esophageal cancer miRNA TRAIL miR-143 miR-122 

Notes

Acknowledgments

This study was supported by The youth innovation fund of the First Affiliated Hospital of Zhengzhou University.

Conflicts of interest

None

References

  1. 1.
    Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–52.CrossRefPubMedGoogle Scholar
  2. 2.
    Pan G, O’Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, et al. The receptor for the cytotoxic ligand trail. Science. 1997;276:111–3.CrossRefPubMedGoogle Scholar
  3. 3.
    Younes M, Georgakis GV, Rahmani M, Beer D, Younes A. Functional expression of trail receptors trail-r1 and trail-r2 in esophageal adenocarcinoma. Eur J Cancer. 2006;42:542–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Kondo K, Yamasaki S, Inoue N, Sugie T, Teratani N, Kan T, et al. Prospective antitumor effects of the combination of tumor necrosis factor-related apoptosis-inducing ligand (trail) and cisplatin against esophageal squamous cell carcinoma. Surg Today. 2006;36:966–74.CrossRefPubMedGoogle Scholar
  5. 5.
    Kim SH, Kim K, Kwagh JG, Dicker DT, Herlyn M, Rustgi AK, et al. Death induction by recombinant native trail and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J Biol Chem. 2004;279:40044–52.CrossRefPubMedGoogle Scholar
  6. 6.
    Zheng SJ, Wang P, Tsabary G, Chen YH. Critical roles of trail in hepatic cell death and hepatic inflammation. J Clin Invest. 2004;113:58–64.PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRefPubMedGoogle Scholar
  8. 8.
    Croce CM, Calin GA. MiRNAs, cancer, and stem cell division. Cell. 2005;122:6–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Gu J, Wang Y, Wu X. MicroRNA in the pathogenesis and prognosis of esophageal cancer. Curr Pharm Des. 2013;19:1292–300.CrossRefPubMedGoogle Scholar
  10. 10.
    Liu SG, Qin XG, Zhao BS, Qi B, Yao WJ, Wang TY, et al. Differential expression of miRNAs in esophageal cancer tissue. Oncol Lett. 2013;5:1639–42.PubMedCentralPubMedGoogle Scholar
  11. 11.
    Wu BL, Xu LY, Du ZP, Liao LD, Zhang HF, Huang Q, et al. Li EM: miRNA profile in esophageal squamous cell carcinoma: downregulation of mir-143 and mir-145. World J Gastroenterol. 2011;17:79–88.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Liu R, Liao J, Yang M, Sheng J, Yang H, Wang Y, et al. The cluster of mir-143 and mir-145 affects the risk for esophageal squamous cell carcinoma through co-regulating fascin homolog 1. PLoS One. 2012;7:e33987.PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Ni Y, Meng L, Wang L, Dong W, Shen H, Wang G, et al. MicroRNA-143 functions as a tumor suppressor in human esophageal squamous cell carcinoma. Gene. 2013;517:197–204.CrossRefPubMedGoogle Scholar
  14. 14.
    Zhang W, Cai R, Luo J, Wang Y, Cui Q, Wei X, et al. The oncolytic adenovirus targeting to tert and rb pathway induced specific and potent anti-tumor efficacy in vitro and in vivo for hepatocellular carcinoma. Cancer Biol Ther. 2007;6:1726–32.CrossRefPubMedGoogle Scholar
  15. 15.
    Liu J, Ma L, Li C, Zhang Z, Yang G, Zhang W. Tumor-targeting trail expression mediated by miRNA response elements suppressed growth of uveal melanoma cells. Mol Oncol. 2013;7:1043–55.CrossRefPubMedGoogle Scholar
  16. 16.
    Bo Y, Guo G, Yao W. MiRNA-mediated tumor specific delivery of trail reduced glioma growth. J Neurooncol. 2013;112:27–37.CrossRefPubMedGoogle Scholar
  17. 17.
    Zhao Y, Li Y, Wang L, Yang H, Wang Q, Qi H, et al. MicroRNA response elements-regulated trail expression shows specific survival-suppressing activity on bladder cancer. J Exp Clin Cancer Res. 2013;32:10.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Hu J, Xu Y, Hao J, Wang S, Li C, Meng S. Mir-122 in hepatic function and liver diseases. Protein Cell. 2012;3:364–71.CrossRefPubMedGoogle Scholar
  19. 19.
    Ma L, Liu J, Shen J, Liu L, Wu J, Li W, et al. Expression of mir-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells. Cancer Biol Ther. 2010;9:554–61.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of Thoracic SurgeryThe First Affiliated Hospital of Zhengzhou UniversityZhengzhouChina
  2. 2.Department of OncologyThe First Affiliated Hospital of Zhengzhou UniversityZhengzhouChina

Personalised recommendations